乙肝肝硬化血清透明质酸与HBV DNA的相关性

目的:探讨乙肝肝硬化患者血清透明质酸与HBV DNA水平的相关性.方法:收集乙肝肝硬化患者144例,其中女性42例,男性102例,平均年龄(54.42±11.53)岁,Child pugh A级42例,Child pugh B级40例,Child pugh C级62例,采用放射免疫法检测血清透明质酸,荧光定量PCR检测血清HBV DNA水平,对血清透明质酸、血清HBV DNA水平进行统计并分析两者之间的关系.结果:随着乙肝肝硬化Child分级的加重,患者的血清透明质酸水平也增高,不同分级之间的差异有统计学意义(174.10μg/L±127.98μg/Lvs421.35μg/L±176.96μg/Lvs903.58μg/L±212.02μg/L,P<0.01).不同Childpugh分级患者的血清HBV DNA水平差异无统计学意义(P>0.05).不同Child pugh分级患者的血清HBV DNA和透明质酸水平无显著相关性(P>0.05).结论:随着患者的Child pugh分级升高,HA水平显著增高,说明HA是反映肝硬化程度的敏感指标;乙肝肝硬化患者HBV DNA与肝硬化程度无显著相关,血清透明质酸与HBV DNA水平之间也无显著相关性,因此抗病毒和抗纤维化治疗对乙肝肝硬化患者同等重要.

Correlation between serum hyaluronic acid and HBV DNA levels in patients with hepatitis B-associated cirrhosis

AIM:To investigate the relationship between serum hyaluronic acid (HA) and hepatitis B virus (HBV) DNA levels in patients with hepatitis B-associated cirrhosis.METHODS:The clinical data for 144 patients diagnosed with hepatitis B-associated cirrhosis were analyzed.There were 42 females and 102 males,and their average age was 54.42 ± 11.53 years.These patients were divided into three groups based on Child-Pugh grade:A,B,and C.Serum HA was determined by radioimmunoassay and serum HBV DNA was determined by fluorescent quantitative PCR.The relationship between serum HA levels and HBV DNA levels was analyzed.RESULTS:Serum levels of HA increased significantly in patients with hepatitis B-associated cirrhosis and positively correlated with the Child-Pugh grade (174.10 μg/L ± 127.98 μg/L vs 421.35 μg/L ± 176.96 μg/L vs 903.58 μg/L ± 212.02 μg/L,all P < 0.01).There were no significant differences in serum HBV DNA levels among the three groups of patients (P > 0.05).Serum HA levels had no significant correlation with serum HBV DNA levels in patients with hepatitis B-associated cirrhosis (P > 0.05).CONCLUSION:HA is a promising marker for hepatic fibrosis in patients with chronic hepatitis B.Serum HBV DNA levels had no significant correlation with liver cirrhosis grade or serum HA levels in patients with hepatitis B-associated cirrhosis.Anti-virus and anti-cirrhosis treatments are equally important for patients with hepatitis B-associated cirrhosis.